Sardona Therapeutics is a spinoff from UCLA, developing first in class small molecule drugs precisely targeting RNA regulators in therapy resistant cancers. Based on our proprietary platform technologies, we are currently advancing two pre-clinical stage therapeutic programs, that have broad application in therapy resistant cancers. Beyond that, we also have a robust pipeline of novel targets with compelling genetic and preclinical validation.
At Sardona Therapeutics, we are a small team of driven, enthusiastic professionals and build on the deep scientific knowledge of our founders and advisors who are thought leaders in their fields spanning key scientific and clinical disciplines. Our team has successfully developed FDA-approved drugs before.